Eli Lilly’s extension of its SmartDepot technology evaluation agreement through October 2026, paired with the company’s recent pivot toward oral GLP-1 candidates such as the April-approved Foundayo and a June 2025 licensing deal with Camurus for lipid-based long-acting injectables, has kept trader consensus tilted against a full commercial license by the deadline. The ultrasonic spray-drying sustained-release microsphere platform remains in active preclinical assessment for Lilly’s peptide pipeline, yet competing delivery options and a broader shift away from traditional depot formulations have introduced meaningful uncertainty. With roughly five months remaining, any milestone data release or joint committee update could still shift implied probabilities, but current sentiment reflects the absence of binding commercial terms to date.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트신규
신규
2026.10.07
신규
신규
2026.10.07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s extension of its SmartDepot technology evaluation agreement through October 2026, paired with the company’s recent pivot toward oral GLP-1 candidates such as the April-approved Foundayo and a June 2025 licensing deal with Camurus for lipid-based long-acting injectables, has kept trader consensus tilted against a full commercial license by the deadline. The ultrasonic spray-drying sustained-release microsphere platform remains in active preclinical assessment for Lilly’s peptide pipeline, yet competing delivery options and a broader shift away from traditional depot formulations have introduced meaningful uncertainty. With roughly five months remaining, any milestone data release or joint committee update could still shift implied probabilities, but current sentiment reflects the absence of binding commercial terms to date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
마켓 개설일: May 5, 2026, 8:02 PM ET
거래량
$8,308종료일
2026.10.07마켓 개설일
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s extension of its SmartDepot technology evaluation agreement through October 2026, paired with the company’s recent pivot toward oral GLP-1 candidates such as the April-approved Foundayo and a June 2025 licensing deal with Camurus for lipid-based long-acting injectables, has kept trader consensus tilted against a full commercial license by the deadline. The ultrasonic spray-drying sustained-release microsphere platform remains in active preclinical assessment for Lilly’s peptide pipeline, yet competing delivery options and a broader shift away from traditional depot formulations have introduced meaningful uncertainty. With roughly five months remaining, any milestone data release or joint committee update could still shift implied probabilities, but current sentiment reflects the absence of binding commercial terms to date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
거래량
$8,308종료일
2026.10.07마켓 개설일
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s extension of its SmartDepot technology evaluation agreement through October 2026, paired with the company’s recent pivot toward oral GLP-1 candidates such as the April-approved Foundayo and a June 2025 licensing deal with Camurus for lipid-based long-acting injectables, has kept trader consensus tilted against a full commercial license by the deadline. The ultrasonic spray-drying sustained-release microsphere platform remains in active preclinical assessment for Lilly’s peptide pipeline, yet competing delivery options and a broader shift away from traditional depot formulations have introduced meaningful uncertainty. With roughly five months remaining, any milestone data release or joint committee update could still shift implied probabilities, but current sentiment reflects the absence of binding commercial terms to date.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문